DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,565 filers reported holding DANAHER CORPORATION in Q2 2020. The put-call ratio across all filers is 1.06 and the average weighting 0.7%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $87,351,362 | +88375.0% | 397,208 | -3.5% | 0.14% | -1.4% |
| Q2 2023 | $98,730 | -15.6% | 411,663 | -11.3% | 0.15% | -23.0% |
| Q1 2023 | $116,953 | +16.5% | 464,269 | +22.7% | 0.19% | +27.3% |
| Q4 2022 | $100,392 | -99.9% | 378,448 | +17.2% | 0.15% | +1.4% |
| Q3 2022 | $83,397,000 | -10.8% | 323,032 | -12.4% | 0.15% | -14.9% |
| Q2 2022 | $93,494,000 | -21.8% | 368,843 | -9.5% | 0.17% | -3.3% |
| Q1 2022 | $119,538,000 | -41.3% | 407,531 | -34.1% | 0.18% | -33.8% |
| Q4 2021 | $203,479,000 | +78.2% | 618,477 | +64.9% | 0.27% | +52.0% |
| Q3 2021 | $114,206,000 | +33.8% | 375,138 | +17.9% | 0.18% | +35.6% |
| Q2 2021 | $85,385,000 | -41.6% | 318,186 | -51.0% | 0.13% | -48.6% |
| Q1 2021 | $146,244,000 | +6.0% | 649,744 | +4.6% | 0.26% | +1.6% |
| Q4 2020 | $137,992,000 | +60.7% | 621,220 | +55.8% | 0.25% | +19.9% |
| Q3 2020 | $85,859,000 | +8.4% | 398,690 | -11.0% | 0.21% | +5.0% |
| Q2 2020 | $79,194,000 | -19.4% | 447,813 | -36.9% | 0.20% | -33.0% |
| Q1 2020 | $98,202,000 | +1.7% | 709,352 | +12.7% | 0.30% | +85.2% |
| Q4 2019 | $96,595,000 | +29.6% | 629,453 | +22.0% | 0.16% | +3.2% |
| Q3 2019 | $74,519,000 | -44.3% | 516,014 | -44.9% | 0.16% | +273.8% |
| Q2 2019 | $133,888,000 | +114.5% | 937,066 | +98.2% | 0.04% | -56.7% |
| Q1 2019 | $62,413,000 | +53.0% | 472,885 | +19.5% | 0.10% | +38.6% |
| Q4 2018 | $40,794,000 | -12.0% | 395,650 | -7.3% | 0.07% | -17.6% |
| Q3 2018 | $46,377,000 | -8.9% | 426,901 | -17.3% | 0.08% | -17.5% |
| Q2 2018 | $50,901,000 | +15.4% | 515,912 | +14.5% | 0.10% | +5.1% |
| Q1 2018 | $44,103,000 | +70.0% | 450,529 | +61.2% | 0.10% | +27.3% |
| Q4 2017 | $25,937,000 | +21.9% | 279,439 | +12.7% | 0.08% | +13.2% |
| Q3 2017 | $21,272,000 | +13.9% | 247,979 | +12.0% | 0.07% | +13.3% |
| Q2 2017 | $18,684,000 | +22.7% | 221,423 | +24.4% | 0.06% | +46.3% |
| Q1 2017 | $15,225,000 | +67.5% | 177,994 | +52.5% | 0.04% | +51.9% |
| Q4 2016 | $9,088,000 | +385.0% | 116,755 | +388.4% | 0.03% | +350.0% |
| Q3 2016 | $1,874,000 | +134.8% | 23,906 | +174.9% | 0.01% | +100.0% |
| Q2 2016 | $798,000 | -15.6% | 8,697 | -13.1% | 0.00% | -50.0% |
| Q1 2016 | $946,000 | -58.3% | 10,003 | -59.0% | 0.01% | -57.1% |
| Q4 2015 | $2,267,000 | +0.2% | 24,385 | -8.0% | 0.01% | +7.7% |
| Q3 2015 | $2,262,000 | -0.2% | 26,517 | +0.1% | 0.01% | +18.2% |
| Q2 2015 | $2,266,000 | -3.3% | 26,478 | -4.1% | 0.01% | +10.0% |
| Q1 2015 | $2,343,000 | -29.1% | 27,598 | -28.4% | 0.01% | -23.1% |
| Q4 2014 | $3,304,000 | +76.3% | 38,570 | +60.8% | 0.01% | +85.7% |
| Q3 2014 | $1,874,000 | +4.9% | 23,985 | +5.6% | 0.01% | +16.7% |
| Q2 2014 | $1,787,000 | +17.9% | 22,715 | +14.6% | 0.01% | +20.0% |
| Q1 2014 | $1,516,000 | -10.7% | 19,828 | -9.9% | 0.01% | -16.7% |
| Q4 2013 | $1,698,000 | +124.9% | 22,002 | +101.6% | 0.01% | +100.0% |
| Q3 2013 | $755,000 | +212.0% | 10,915 | +186.7% | 0.00% | +200.0% |
| Q2 2013 | $242,000 | +868.0% | 3,807 | +851.8% | 0.00% | – |
| Q1 2013 | $25,000 | – | 400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |